Trial of Intravenous Immune Globulin in Dermatomyositis

2022189 citationsJournal Articlebronze Open Access

Authors

Rohit Aggarwal · University of Pittsburgh

Christina Charles‐Schoeman · University of California, Los Angeles

Joachim Schessl · Hospital of the University of Pennsylvania

Zsuzsanna Bata‐Csörgõ · University of Szeged

Mazen M. Dimachkie · Hospital of the University of Pennsylvania

Zoltán Griger · University of Debrecen

Sergey Moiseev

Abstract

In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).

Topics & Keywords

Inflammatory Myopathies and Dermatomyositis Immunodeficiency and Autoimmune Disorders Eosinophilic Disorders and Syndromes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 387, Issue 14, pp. 1264-1278

DOI: 10.1056/nejmoa2117912

Field-Weighted Citation Impact: 27.42